Prince Henry's Institute of Medical Research, Monash Medical Centre, Clayton, Victoria 3168, Australia.
Prog Cardiovasc Dis. 2010 Mar-Apr;52(5):393-400. doi: 10.1016/j.pcad.2009.12.003.
Aldosterone is currently thought to exert its physiologic effects by activating epithelial mineralocorticoid receptors, and its pathologic effects on the cardiovascular system via mineralocorticoid receptors in the heart and blood vessels. Recent studies have extended this understanding to include a reevaluation of the roles of aldosterone and mineralocorticoid receptor activation in blood pressure control; the rapid, nongenomic effects of aldosterone; the role of cortisol as a mineralocorticoid receptor agonist under conditions of redox change/tissue damage/reactive oxygen species generation; the growing consensus that primary aldosteronism accounts for approximately 10% of all essential hypertension; recent new insights into the cardioprotective role of spironolactone; and the development of third- and fourth-generation mineralocorticoid receptor antagonists for use in cardiovascular and other inflammatory disease. These findings on aldosterone action and mineralocorticoid receptor blockade are analyzed in the context of the prevention and treatment of cardiovascular disease.
醛固酮目前被认为通过激活上皮性盐皮质激素受体发挥其生理作用,通过心脏和血管中的盐皮质激素受体发挥其对心血管系统的病理作用。最近的研究扩展了这一认识,包括重新评估醛固酮和盐皮质激素受体激活在血压控制中的作用;醛固酮的快速、非基因组作用;在氧化还原变化/组织损伤/活性氧产生的情况下,皮质醇作为盐皮质激素受体激动剂的作用;越来越多的共识认为原发性醛固酮增多症占所有原发性高血压的 10%左右;最近对螺内酯的心脏保护作用的新见解;以及第三代和第四代盐皮质激素受体拮抗剂在心血管和其他炎症性疾病中的应用。这些关于醛固酮作用和盐皮质激素受体阻断的发现,是在心血管疾病的预防和治疗背景下进行分析的。